ISSN 1866-8836
Клеточная терапия и трансплантация

Iron overload: causes, assessment methods, significance in transplantation setting and therapeutically approaches

M. Ivanova, E. Morozova, Y. Vasilieva, Y. Rudnitskaya, R. Nabiev, L. Zubarovskaya, B. Afanasyev

Memorial R. M. Gorbacheva Institute of Children Hematology and Transplantation, St. Petersburg Pavlov State Medical University, St. Petersburg, Russia

Maria Ivanova, Memorial R.M. Gorbacheva Institute of Children Hematology and Transplantation, St. Petersburg Pavlov State Medical University, 6/8, Tolstoy str., St. Petersburg, 199044, Russia
Phone: +7 (812) 233-17-20, E-mail:
doi 10.3205/ctt-2009-en-000037.01
Submitted 19 January 2009
Accepted 12 October 2009
Published 30 December 2009


Posttransfusional iron overload is a relatively common complication related to long-term treatment of various haematological diseases. Haematopoietic stem cell transplant recipients - both allogenic and autologous - often present with iron overload because of exposure to red blood cell (RBC) transfusions during the initial treatment and in the post transplant period. Despite these there are also some conditions which contribute to increased risk for iron overload.

A variety of early post transplantant complications including infections, liver function abnormalities, and hepatic sinusoidal obstruction syndrome have been connected with iron overload. The late morbidity of iron overload is primarily due to involvement of heart and liver. Iron overload has been reported to increase the risk of infections late after transplantation.

It has been suggested that all candidates for and all survivors of haematopoietic stem cell transplantation HSCT should be screened for iron overload at various time points before and after transplantation. Serum ferritin is sensitive but not specific for iron overload and is a poor predictor of body iron burden. It can be used for iron overload assessment, but it is recommended to use it together with some other parameters.

Adequate chelation therapy can reduce iron burden and complications and should be administered as soon as there are signs of iron overload.

More studies are needed to better define the natural history of iron overload and its impact on late morbidity and mortality in transplant recipients.


Complications, bone marrow transplantation, iron metabolism, chelating therapy, iron overload


Iron is an essential microelement in human body [17]. It is quite important co-factor of enzymes active in mitochondrial respiratory chain, citrate cycle, DNA synthesis, and plays a central role in oxygen binding to hemoglobin and myoglobin; iron-containing proteins are indispensable for collagen, tyrosine and catecholamine metabolism. But free, non-chelated iron, due to its catalytic action in a redox-reaction may form dangerous hydroxyl radicals that may cause cell death resulting from peroxidative damage of cell membranes. In the course of evolutionary development, this was resolved by formation of specialized molecules adapted to its intestinal absorption from food, its transport and deposition in soluble, non-toxic form.

Three crucial mechanisms are important for iron homeostasis, as follows:

•    Iron absorption from food products in small intestine which, generally, compensates for physiological losses;

•    IRE/IRP (Iron Responsive Element/Iron Regulatory Protein) system means intracellular iron uptake or its deposition in complex with ferritin. These processes provide cellular demands of iron and, at the same time, preventing toxic effect of iron overload;

•    Erythrophagocytosis and recirculation of erythrocyte-derived iron, thus ensuring main requirements for iron during erythropoiesis.

These three mechanisms provide stabilization of iron stores in the organism, as well as its intracellular metabolism and bioavailability [17, 34].

The key point of intestinal iron absorption is hepcidin-mediated regulation system.  Hepcidin, a peptide hormone made in the liver, is the principal regulator of systemic iron homeostasis. Hepcidin controls plasma iron concentration and tissue distribution of iron by inhibiting intestinal iron absorption, iron recycling by macrophages, and iron mobilization from hepatic stores. Hepcidin acts by inhibiting cellular iron efflux through binding to and inducing the degradation of ferroportin, the sole known cellular iron exporter. Synthesis of hepcidin is homeostatically increased by iron loading and decreased by anemia and hypoxia. Hepcidin is also elevated during infections and inflammation, causing a decrease in serum iron levels and contributing to the development of anemia of inflammation, probably as a host defense mechanism to limit the availability of iron to invading microorganisms [58].

Disorders associated with altered iron metabolism may be arbitrarily classified in two large groups: iron-deficient and iron overload states.

Iron deficiencies may be caused by alimentary factors (low amount of iron in food), increased iron losses (e.g., due to bleedings) and disturbed iron absorption (Crohn’s or celiac disease, surgical removal of part of intestine, the use of some medications etc).

The most common reasons for conditions, associated with iron overload, are as follows [60, 74]:

1. Genetic alterations of iron metabolism

•    Hereditary haemochromatosis types 1-4

HFE-associated HH (type 1)

  C282Y homozygosity

  C282Y/H63D compound heterozygosity

Non-HFE-associated HH

  Type 2A HJV variants

  Type 2B hepcidin variants

  Type 3 TfR variants

  Type 4 ferroportin variants

•    Acoeruloplasminaemia

•    Atransferrinaemia  

2. Genetic disturbances of erythropoiesis, and/or life cycle of red blood cells (hereditary dyserythropoietic, haemolytic anaemias, including thalassemias, sickle cell anaemia (SCA),  Blakmond-Diamond anaemia)

3. Acquired conditions requiring long-term, repeated haemotransfusions (myelodysplastic syndrome (MDS), acute leukaemias, myelofibrosis, multiple myeloma etc)

4. Chronic liver diseases (hepatitis, alcohol abuse, nonalcoholic steatohepatitis etc)

Transfusion-associated iron overload

Iron overload due to RBC transfusions is a relatively common complication related to long-term treatment of various haematological diseases. Each unit of blood contains 200 mg of haeme iron, more than 100-fold than a daily amount of iron normally absorbed from the diet. Transfused red blood cells, upon their senescence, are degraded and their iron is re-utilized by resident macrophages. These fractions of bioavailable iron, after binding to transferring, are released into the circulation, and dissipate to body tissues. Iron overload is an inevitable consequence of regular transfusion therapy [37]. After receiving 20 lifetime units of packed red blood cells, patients can become iron overloaded. No matter how many years pass between transfusions, the dangers are the same, because the body has no way actively excrete excess iron. Iron overload is proportional to transfusion burden [67, 57].

When iron overload is evident, transferrin becomes saturated, thus leading to increased non-transferrin bound iron (NTBI) in blood plasma. Whereas tissue uptake of transferrin-bound iron is regulated by expression of membrane-bound transferrin receptor (responsible for transport of transferrin into cells [4]), excess of NTBI is often absorbed by susceptible tissues. This leads to pools of unbound iron within cells, which mediate toxicity by the formation of reactive oxygen species (ROS) [30]; Figure 1.

Figure 1.


ROS react with cellular components such as the plasma membrane, lysosomes, and organelle membranes, leading to cellular leakage, dysfunction, and, ultimately, cell death [33].

The organ damage that occurs with transfusional iron overload is similar to that seen in hereditary haemochromatosis, although iron accumulation occurs more rapidly, and deposition of iron in resident tissue macrophages is proportionally greater [43, 74, 77]. Hereditary haemochromatosis is characterized by iron accumulation primarily in the liver, heart, and pancreas. However, whereas chronic anaemias are related to errors in erythropoiesis, the main cause of haemochromatosis is a reduction or absence in expression of hepcidin (in particular, due to the haemochromatosis gene (HFE) mutations) [43, 74, 77]. 

Under steady-state conditions, hepcidin prevents excessive intestinal absorption of iron and its release from macrophages. Therefore it minimizes the amount of iron that enters into plasma. However, in conditions of chronic iron overload, blood transfusion leads to an increase in erythrocytes, which are broken down by macrophages. This initially results in an increase in iron levels in resident tissue macrophages. Hepcidin expression also downregulates iron release from this system, leading to a “build-up” in the reticuloendothelial system and its possible saturation (a stage that is reduced or absent in patients with haemochromatosis). Subsequently, iron is deposited in various tissues, thus leading to tissue damage [43, 46, 63].

It is well established that, prior to advent of iron-chelating therapy, cardiomyopathy and liver fibrosis associated with iron overload were among the leading causes of death among children with thalassemia [15, 61]. The role of iron overload in MDS patients is also well established. There are different data concerning overall survival and progression free survival in MDS patients according to transfusion dependency and serum ferritin level [49, 50, 51, 75, 78]. Studies have indicated that iron overload following RBC transfusions was an independent, adverse prognostic factor for overall survival (OS) and leukemia-free survival (LFS): OS and LFS were significantly shorter in transfusion-dependent patients with MDS than in those who were not transfusion dependent.

Accurate assessment of body iron burden is necessary to diagnose iron overload and also to effectively manage therapy.

Assessment of body iron stores

There are numerous methods available for the detection and assessment of iron levels, both as total body and specific tissue levels. Because transfusions may lead to rapid iron accumulation, monitoring a patient's number of transfused blood units, serum ferritin levels, and/or liver iron concentrations can play an essential role in the management of iron overload. Each method is associated with advantages and disadvantages [19, 52].

Diagnosis of postransfusional iron overload:

•    Established
      –    Ferritin
      –    Liver iron concentration (biopsy)

•     Investigational
      –    Biomagnetic liver susceptometry (SQUID)
      –    Magnetic resonance imaging (MRI)

Ferritin is inexpensive, noninvasive, and widely available method, which provides reliable estimates of iron burden when performed on a serial basis. Serum ferritin levels consistently >1000 mcg/L are suggestive of iron overload [62, 70], and in the absence of appropriate therapy are associated with adverse clinical outcomes in iron overload [50, 62, 75]. Ferritin is the simplest method for assessment of iron overload, but it has limitations of the value [13]. The advantages and disadvantages of the ferritin measure are summarized
in Table 1.



•  Easy to assess

•  Indirect measurement of iron burden

•  Inexpensive

•  Fluctuates in response to inflammation, abnormal liver function, metabolic deficiencies

•  Repeat measures are useful for monitoring chelation therapy

•  Serial measurement required

•  Positive correlation with morbidity and mortality

Table 1. Ferritin as a marker of iron overload

Liver biopsy provides direct information about the structure, function, and extent of iron deposition within the liver, and may also have prognostic value.

Liver iron concentration (LIC) predicts total body storage iron [5, 13], but measuring LIC by Liver Biopsy has its limitations, too
(Table 2).



•  Direct measurement of LIC

•  Invasive, painful procedure associated with potentially serious complications

•  Validated reference standard

•  Risk of sampling error, especially in patients with cirrhosis

•  Quantitative, specific, and sensitive

•  Requires skilled physicians and standardized laboratory techniques

•  Allows for measurement of nonhaeme storage iron

•  Poorly correlated with cardiac iron

•  Provides information on liver histology/pathology

•  Difficult follow-up

•  Positive correlation with morbidity and mortality

Table 2. LIC as a marker of iron overload

Magnetic resonance imaging (MRI) provides a noninvasive, quantitative method of estimating parenchymal iron levels. In principle, MRI can be used to quantify iron stores wherever they exist in the body. In practice, MRI has been investigated in the assessment of hepatic, cardiac, and anterior pituitary iron stores. MRI measures tissue iron concentration indirectly via the detection of the paramagnetic influences of storage iron (ferritin and haemosiderin) on the proton resonance behavior of tissue water [39]. The longitudinal (R1) and transverse (R2) nuclear magnetic relaxation rates of nearby solvent water protons can then be calculated. Both R1 and R2 rates are increased when interacting with paramagnetic particles such as iron. R2 (or spin-echo imaging) is preferable to R1 for determining LIC, since ferritin enhances the relaxation of both R1 and R2, while haemosiderin only has a strong R2 relaxation accelerating effect. Gradient echo imaging produces images for calculating T2* and R2*, where R2* = 1000/T2*. A T2* of 20 ms is equivalent to an R2* of 50 Hz. MRI provides a non-invasive alternative to liver biopsy, and may actually be more accurate in patients with heterogeneous liver iron deposition (such as those with cirrhosis) since it measures iron in the whole organ. In addition, the pathologic status of the liver can also be assessed using MRI [3, 25, 27]. MRI remains the only noninvasive modality in clinical use with the ability to detect cardiac iron deposition. T2* MRI is rapidly becoming the new standard for measuring cardiac iron levels. One study found that below a myocardial T2* of 20 ms, there was a progressive and significant decline in left ventricular ejection fraction (LVEF). In general, the lower the T2*, the higher the risk of cardiac dysfunction, with a T2* <8 ms suggestive of severe iron overload [3].

SQUID stands for Superconducting Quantum Interference Device. This imaging modality uses a very low-power magnetic field with sensitive detectors that measure the interference of iron within the field. The sensor requires a cryogenic environment, since it must be superconducting to operate. Although SQUID is still considered investigational, linear correlations have been demonstrated between SQUID measurements and liver biopsy LIC levels [14, 16, 59, 66].

Although SQUID directly measures the magnetic susceptibility of ferritin and haemosiderin, at present it does not have sufficient spatial or temporal resolution to evaluate myocardial iron. In a large clinical trial, LIC data obtained by SQUID were shown to underestimate LIC values obtained from biopsy by a factor of 0.46 [64].

Both SQUID and MRI have linear correlations with LIC assessed by biopsy, but they provide indirect measurement of LIC, have high cost and as highly specialized equipment requires dedicated technician [3, 7]. Limitations of these methods are summarized in Table 3.





Able to analyze whole organ
Pathologic status of the liver can be assessed in parallel
Allows longitudinal follow-up of patients

Requires imager with a dedicated imaging method
Indirect measurement of LIC


Measurement may be repeated frequently
Linear correlation with LIC assessed by biopsy

Limited availability
High cost
Indirect measurement of LIC
Complex procedure requiring trained personnel
Underestimates LIC versus biopsy

Table 3. SQUID and MRI as a markers of iron overload

Various additional laboratory tests have been developed to assess iron overload. While not widely available, they may hold promise of providing additional clinical information.

•    Serum ferritin iron may be less susceptible than serum ferritin to confounding factors such as inflammation [36].

•    Serum transferrin receptor concentration has been used to detect both iron deficiency and excess iron. In the presence of iron overload, cells downregulate transferrin receptor expression, and therefore serum transferrin receptor concentration would be expected to be reduced [41].

•    Non-transferrin-bound iron (NTBI) - which is normally not found in plasma, increased rapidly during conditioning therapy and contribute to .oxidative stress after high-dose radiochemotherapy [24].

•    Labile plasma iron (LPI) quantifies the oxidative activity of the patient's plasma-borne NTBI. In theory, this test can be used as a direct measure of iron overload. One approach to measuring LPI is to measure the reactive radicals generated in the subject's blood by exposure to ascorbate, compared to those generated after the addition of a chelating agent (which blocks the oxidative activity of the NTBI) [26].

•    Directly chelatable iron (DCI) is not a test for iron overload per se, but rather an experimental assay for assaying the plasma pool of non-transferrin-bound iron (NTBI).

If to speak about recommendations three guidelines concerning MDS, SCD and thalassemia should be mentioned.

Consensus recommendations developed by leading MDS researchers and clinicians recommend baseline assessment of body iron stores at diagnosis of MDS and at regular intervals – at least every 3 months – thereafter [28]. They recommend that monitoring be performed with a combination of serum ferritin, serum transferrin, and liver MRI [28].

U.S. National Heart, Lung, and Blood Institute (NHLBI) guidelines for the management of sickle cell disease state that, even in patients who receive intermittent transfusions, "a comprehensive program to monitor and treat iron overload is necessary" [56]. NHLBI guidelines state that [56]:

•    Screening for iron overload with serum ferritin testing is recommended at the onset of transfusions.

•    Iron overload is likely to be detected after 20 transfusions.

•    Liver biopsy is the most accurate test for confirming iron overload in SCD.

According to the Thalassaemia International Federation (TIF) Guidelines for Clinical Management, iron overload constitutes "the most important complication in β-thalassemia and the major focus of clinical management") [21].

TIF guidelines recommend screening for iron overload at the onset of transfusions. Iron overload is likely to be detected after the first 10-20 transfusions (near age 3 years) [22]:

•    Monitor serum ferritin at least every 3 months

•    Do not rely on serum ferritin alone

•    Liver iron concentration – determined by biopsy or noninvasively by MRI or SQUID – is the reference standard for estimating iron loading

Thus, summarized these guidelines,  it can be recommended for all haematological conditions to accurately evaluate and record the iron input, start screening for iron overload at the time of beginning the initial treatment then  after each 10-20 transfusions and every three months.  Serum ferritin can be used as the basic parameter, but though it is not highly specific marker, it shouldn’t be used alone. LIC measurement by biopsy (if indicated) or by MRI or SQUID (if available) is desirable. Assessment of the heart iron by MRI T2* (cardiac risk), at least once is also recommended, If positive, it should be used as the main result to set treatment [16].

Iron overload in transplantation setting

Iron overload commonly accompanies bone marrow transplantation [73]. Haematopoetic cell transplant recipients - both allogenic and autologous – often present with iron overload because of exposure to RBC transfusions, both during the initial treatment of their disease and in the post transplant period [48]. Despite these there are some conditions which contribute to increased risk for iron overload: the genetic background (heterozygous C282Y mutations can be identified in ~30% of patients with MDS); chemo/radiotherapy (total body irradiation (TBI)/alkylator-induced alterations which increase NTBI and decrease total radical-trapping antioxidant activity in plasma); chronic infections and inflammation; haemolytic disorders induced by immunosuppressive agents (cyclosporine and tacrolimus) [60]. Even in patients without a history of transfusions, a predictable increase in serum iron, transferring saturation, ferritin and non-transferrin bound iron has been observed in the early post transplantat period [11, 31, 71].

There are several studies concerning importance of iron overload in transplantation setting [9, 20, 35, 47, 53, 60, 69, 73, 76]. The majority of data are devoted to thalassemia and MDS patients. Concerning thalassemia patients hepatomegaly, hepatic fibrosis due to iron overload and poor compliance with iron chelation were identified as being independent prognostic factors, and a classification system according to these factors was developed and adopted by most centers [71]. Age is also an important factor when predicting outcome, with adult patients usually having a poorer outcome when compared to children [44]. In MDS the recently defined WHO classification–based Prognostic Scoring System (WPSS) (which include the transfusion dependency as a prognostic factor) was able to identify five risk groups of untreated MDS patients with different survival and risk of  leukaemic progression, compared with the four groups defined by IPSS [32]. It was observed in addition that WPSS has an independent prognostic significance on both overall survival (OS) and probability of relapse in MDS patients undergoing allo-HSCT. This score appeared to improve post transplantation prognostic stratification with respect to the International prognosis scoring system (IPSS). Considering MDS patients without excess of  blasts, the WPSS identified two groups of patients (low vs. intermediate risk) with a significant difference in OS and treatment related mortality (TRM), whereas in the same group of patients IPSS failed to stratify the prognosis [49]. Interestingly, both WHO classification and WPSS maintained their prognostic effect on post transplantation outcome also in specific subsets of patients, such as patients older than 50 years as well as patients receiving reduce intensity chemotherapy (RIC). This observation might be relevant in the light of the increased number of RIC performed in MDS in most recent years, after the demonstration of their efficacy in allowing engraftment and in decreasing TRM in patients ineligible for standard conditioning allo-HSCT [49]. In particular, WHO classification and WPSS show a relevant prognostic value in post transplantation outcome of MDS patients and might help decision making in transplantation.

Armand et al. estimated that iron overload could be a significant contributor to TRM for patients with haematologic malignancies undergoing HSCT. They studied 590 patients who underwent myeloablative allogeneic HSCT at their institution, and on whom pre-transplantation serum ferritin was available. An elevated pretransplantation serum ferritin level was strongly associated with lower OS and DFS. Subgroup multivariable analyses demonstrated that this association was restricted to patients with acute leukemia or MDS [9].

Altes et al. concluded that very high level (VHL) of ferritin and transferring saturation (TS) >/=100% at the time of conditioning are associated with an increase in toxic deaths after transplant [2].

Several other studies also confirm that iron overload can increase morbidity and mortality in transplanted patients [9, 20, 35, 47, 53, 60, 71, 73, 76].

Early and late complications of HCT that have been associated with iron overload are summarized in Table 4.



Early (<1 year) post transplant


Acute GVHD

Hepatic sinusoidal obstruction syndrome

Nonrelapse mortality



Mucormycosis, invasive aspergillosis, Listeria monocytogenes and other infections

No clear evidence available, elevated ferritin might increase risk

Iron overload might increase risk

Elevated ferritin associated with increased risk in allogenic and autologous recipients

Late (>1 year) post transplant


Chronic GVHD

Liver function abnormalities

Cardiac late effects

Nonrelapse mortality



Mucormycosis, invasive aspergillosis, and other infections

No clear evidence available, elevated ferritin might decrease risk

Iron overload might increase risk

Iron overload might increase risk

No clear evidence available

Table 4. Iron overload-related complications after HSCT [43]

A variety of early post transplantant complications including infections, liver function abnormalities, and the hepatic sinusoidal obstruction syndrome have been connected with iron overload [35, 38, 47, 53, 54, 76].

The late morbidity of iron overload is primarily due to involvement of heart and liver. Although iron-related liver function abnormalities have been reported, there are no studies describing the role of iron overload in late onset of cardiomyopathy and hepatic fibrosis in patients transplanted for diseases other than thalassemia [1, 8, 15, 42, 61, 80]. Iron overload has been reported to increase the risk of infections late after transplantation. The impact of iron overload on long-term nonrelapse mortality has not been studied. Iron overload can mimic liver GVHD. Whether it can increase the risk of GVHD is an open question and more investigations are required to confirm this idea [48].

Iron chelation therapy 

The principal goal of chelation therapy is to decrease tissue iron concentrations to lower levels without risk of iron-mediated toxicity. Guidelines for iron overload treatment in MDS patients (IPSS low or intermediate-I, stable disease, candidates for allograft) recommend starting chelation therapy after receiving 20 units of red blood cell transfusions and  clinical evidence of chronic iron overload (serum ferritin levels > 1000 μg/L or liver ferritin < 2 mg/g dry weight) [28]. TIF guidelines also recommend managing iron overload when serum ferritin is >1000 mcg/L [21, 22].  NIH recommends start iron chelation in SCD patients when liver iron stores rise to 7 mg/g dry weight; cumulative transfusion of 120 cc of pure red cells/kg body weight and serum ferritin level in steady-state is >1000 ng/mL [57].

There are no clear-cut guidelines for when to start screen and initiate therapy for iron overload in transplanted patients. End-organ damage related to iron overload is dependent on the rate of iron accumulation and the period of overload state. HSCT recipients frequently get RBC transfusions during their treatment and in the early post transplant period. Decisions regarding management of iron overload should be individualized and be based on several factors including the need of transfusion therapy, time since transplantation, and urgency to reduce body iron stores which is dependent on the presence of liver tests abnormalities or cardiac dysfunction. According to those studies which estimated the role of iron overload on complications and mortality after transplantation, screening and treatment of iron overload might have to be considered in the pre-transplant and early post transplant period. Many patients become transfusion independent with time and if having mild iron overload without signs of organ damage, can be observed without any treatment. There are published recommendations for screening and prevention of late effects of iron overload in HSCT which suggest to monitor the ferritin level at one year post transplant [69].

The treatment modalities for iron overload are summarized in Table 5.

Treatment modality



7 ml/kg body weight weekly

Desferrioxamine (Desferal)

8–12 hours subcutaneous infusion 5–7 days per week; dose, infusion duration, and number of administrations to be decided according to patient age and severity of iron overload

Deferasirox (Exjade)

Once-daily oral dosing; initial daily dose of 20 mg/kg (10–30 mg/kg)

Deferiprone (Ferriprox)

Twice-daily oral dosing; total daily dose of 75 mg/kg

Table 5. Treatment modalities for iron overload

Phlebotomy is a feasible and effective method of iron overload treatment. Its efficacy was demonstrated in many studies [5, 6, 40, 53], but patients with persisting anemia are not able to undergo phlebotomy. Although the use of erytropoiesis stimulating agents to enable phlebotomy has been reported following HSCT, caution should be performed in their use because of recent reports of an increased risk of thromboembolism [10, 68].  Patients not being eligible for phlebotomy can be treated with iron chelators. Deferoxamine (Desferal, Novartis Pharmaceuticals Corporation, USA) has a proven efficacy and safety with decades of experience and has been studied in HCT recipients [29, 30]. The main disadvantages are side effects such as ototoxicity, growth retardation and the inconvenient administration (prolonged daily subcutaneous infusion for 5-7 days) which often leads to poor compliance. Deferiprone is an oral iron chelator, but is not available in all countries, including the Russian Federation, and has not been investigated in HSCT recipients. Deferasirox (Exjad, Novartis Pharmaceuticals Corporation) is a recently introduced oral iron chelator with efficacy similar to deferoxamine [18, 65, 79]. Commonly reported side effects include skin rash, nausea, vomiting and elevation in serum creatinine level. Most of them are mild to moderate and dose-dependent. More experience with its use in HSCT recipients is also needed.

Two iron chelators are currently in earlier stages of clinical trials. Attaching deferoxamine to hydroxyethyl starch creates a high molecular weight compound with a longer circulation time. Studies are underway to seek a dose that would allow acceptable intervals between intravenous infusions while still promoting an effective level of iron excretion. Deferitrin is an orally active tridentate compound from the ferrithiocin class of chelators. Phase I and II studies have not shown evidence of renal toxicity that had been noted in animal studies with some ferrithiocin analogues, and a current dose-escalation study is designed to identify the appropriate strategy for a pivotal trial [23].


1. Disturbed iron balance is a common condition in the patients undergoing intensive chemotherapy, HSCT and multiple RBC transfusions.

2. Iron overload is a subject to iron-chelating therapy because of its negative influence on early postrtansplant complications and even mortality.

3. Although there are no clear guidelines for iron overload screening in HSCT recipients it can be recommended to monitor at least the ferritin level before the transplantation and at one year post transplant.

4. Decision on when to treat must be individualized and depends on transfusion history, ferritin levels, and signs of organ iron toxicity.  

5. More studies are needed to better define the natural history of iron overload and its impact on late morbidity and mortality in transplant recipient.


1. Aldouri MA, Hoffbrand AV, Flynn DM. High incidence of cardiomyopathy in beta thalassaemia patients receiving transfusion and iron chelation: reversal by intensified chelation Acta Hematol. 1990;84(3):113-7. pmid:  2123060.

2. Altes A, Remacha AF, Sarda P, Baiget M, Sureda A, Martino R, Briones J, Brunet S, Canals C, Sierra J. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation Bone Marrow Transplantation. 2002;86(6):443-7.

3. Anderson L, Holden S, Davis B. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–2179. doi:10.1053/euhj.2001.2822.

4. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341:1986-1995.

5. Angelucci E, Brittenham GM, McLaren CE, Ripalti M. Baronciani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J med. 2000;343:327-331.

6. Angelucci E, Muretto P,  Lucarelli G, Ripalti M, Baronciani D, Erer B, et al. Phlebotomy to reduce iron overload in patients cured for thalassemia by bone marrow transplantation. Italian cooperative group for phlebotomy treatment of transplanted thalassemia patients. Blood. 1997;90:994-998.

7. Angelucci E, Giovagnoni A, Valeri G, Paci E, Ripalti M., Muretto P, McLaren C, Brittenham GM., Lucarelli G. Limitations of Magnetic Resonance Imaging in Measurement of Hepatic Iron. 1997;90:4736-4742.

8. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, Ripalti M, Sodani P, Tomassoni S, Visani G, Lucarelli G. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100:17-21.

9. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, Soiffer RJ, Antin JH. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109:4586-4588. 10.1182/blood-2006-10-054924.

10. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anemic patients with cancer: 2006 update. Eur J Cancer. 2007;43:258-270.

11. Bradley SJ, Gosriwitana I, Srichairatanakool S, et al. Non-transferrin-bound iron induced by myeloablative chemotherapy. Br J Haematol. 1997;99:337-343. pmid: 9375751.

12. Brittenham GM, Badman DG, Noninvasive measurement of iron: report of an NIDDK workshop. Blood. 2003;101(1):15-9. doi: 10.1182/blood-2002-06-1723.

13. Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol. 1993;42:81.85. pmid: 8416302.

14. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med. 1982;307(27):1671-5. pmid: 7144866.

15. Brittenham GM, Grifith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in prevention complications of iron overload in patients with talassemia major. N Engl J Med. 1994;331:567-573.

16. Brittenham GM. Noninvasive methods for the early detection of hereditary hemochromatosis. Ann N Y Acad Sci. 1988;526:199-208. doi: 10.1111/j.1749-6632.1988.tb55506.x.

17. Cadet EM, Gadenne D, Capront J. Rochette Donnes recentes sur metabolisme du fer: un etat de transition. La revue de medecine interne. 2005;26:315-324.

18. Cappelini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaodlu L, et al. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with {beta}-thalassemia. Blood. 2006;107:3455-3462. doi: 10.1182/blood-2005-08-3430.

19. Cappellini MD. Diagnosis of Iron Overload The curriculum in iron metabolism and iron disorders. February 2008 /

20. Carmine TC, Evans P, Bruchelt G, et al. Presence of iron catalytic for free radical reactions in patients undergoing chemotherapy: implications for therapeutic management. Cancer Lett. 1995;94:219-226. doi:10.1016/0304-3835(95)03852-N.

21. Chapter 1: Iron Overload. Cappellini N, Cohen A, Eleftheriou A, Piga A, Porter J, eds. In: Guidelines for the Clinical Management of Thalassaemia: Thalassaemia International Federation; 2000:5-7.

22. Chapter 5: Iron Overload. Cappellini N, Cohen A, Eleftheriou A, Piga A, Porter J, eds. In: Guidelines for the Clinical Management of Thalassaemia: Thalassaemia International Federation; 2000:21-35.

23. Cohen AR. New Advances in Iron Chelation Therapy. Haematology. 2006;1:42.

24. Dürken M, Herrnring C, Finckh B, Nagel S, Nielsen P, Fischer R, Berger HM, Moison RMW, Pichlmeier U, Kohlschütter B, Zander AR, Kohlschütter A. Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. Free Rad Biol and Med. 2000;28(6):887-894.

25. Ernst O, Sergent G, Bonvarlet P, et al. Hepatic iron overload: diagnosis and quantification with MR imaging. AJR Am J Roentgenol. 1997;168(5):1205-8.

26. Esposito BP, Breuer W, Sirankapracha P, et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102(7):2670-7. doi: 10.1182/blood-2003-03-0807.

27. Gandon Y, Guyader D, Heautot JF, et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology. 1994;193(2):533-8.

28. Gattermann N, et al. Consensus statement on iron overload in myelodysplastic syndromes. Hematology / Oncology clinics. 2005;19(1):17-25.

29. Gaziev D, Giardini C, Angelucci E, Polchi P, Galimberti M. Baronciani D, et al. Intravenous chelating therapy during transplantation for thalassemia. Hematologica. 1995;80:300-304.

30. Giardini C, Galimberti M, Lucarelli G, Polchi P, Angelucci E,  Baronciani D, et al. Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassemia. Br J Haematol. 1995;89:868-873. pmid: 7772524.

31. Gordon LI, Brown SG, Tallman MS, et al. Sequential changes in serum iron and ferritin in patients undergoing high-dose chemotherapy and radiation with autologous bone marrow transplantation: possible implications for treatment related toxicity. Free Rad Biol Med. 1995;18:383-389. doi: 10.1016/0891-5849(94)E0145-9.

32. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.

33. Halliwell B, Gutteridge JMC, Cross CE. Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med. 1992;119:598-620.

34. Harford JB, Rouault TA, Huebers HA, and Klausner RD. Molecular mechanisms of iron metabolism. In The Molecular Basis of Blood Diseases, G. Stamatoyannopoulos, A. W. Nienhuis, P. W. Majerus and H. Varmus, eds. Philadelphia: W.B. Saunders Co. 1994;351-378.

35. Harrison P, Neilson JR, Marwah SS, et al. Role of non-transferrin bound iron in iron overload and liver dysfunction in long term survivors of acute leukaemia and bone marrow transplantation. J Clin Pathol. 1996;49:853–856.

36. Herbert V, Jayatilleke E, Shaw S, et al. Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. Stem Cells. 1997;15(4):291-6. doi: 10.1002/stem.150291.

37. Hollan SR. Transfusion-associated iron overload. Curr Opin Hematol. 1997;4:436–441. pmid: 9359002.

38. Iglesias-Osma C, Gonzalez-Villaron L, San Miguel JF, et al. Iron metabolism and fungal infections in patients with haematological malignancies. J Clin Pathol. 1995;48:223-225.

39. Jensen PD, Evaluation of iron overload. Br J Haematol. 2004;124(6):697-711. pmid: 15009057.

40. Kamble RT, Selby GB, Mims M, Kharfan-Dabaja MA, Ozer H, George JN. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogenic hematopoetic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:506-510.

41. Khumalo H, Gomo ZA, Moyo VM, et al. Serum transferrin receptors are decreased in the presence of iron overload. Clin Chem. 1998;44(1):40-4.

42. Li CK, Chik KW, Lam CWK, To KF, Yu SCH, Lee V, Shing MMK, Cheung AYK, Yuen PMP. Liver disease in transfusion dependent thalassaemia major. Arch. Dis. Child. 2002;86:344-347.

43. Lichtman SM, Attivissimo L, Goldman IS, Schuster MW, Buchbinder A. Secondary hemochromatosis as a long-term complication of the treatment of hematologic malignancies. Am J Hematol. 1999;61:262-264.

44. Lucarelli G, Clift RA, Galimberti M, et al. Bone marrow transplantation in adult thalassemic patients. Blood. 1999;93:1164-1167.

45. Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. New Engl J Med. 1993;329:840-844.

46. Ma AD, Udden MM.  Iron metabolism, iron overload, and the porphyrias. ASH-SAP. 2007:61-77.

47. Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 1999;24:307-312.

48. Majhail NS, Lazarus NM and Burns LJ. Iron overload in hematopoetic cell transplantation. Bone marrow Transplantation. 2008;41:997-1003.

49. Malcovati L, Alessandrino EP, Giovanni M, Bacigalupo A, et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood. 2008;112(3):895-902. doi: 10.1182/blood-2008-03-143735.

50. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006;91:1588-1590.

51. Malcovati L, Della Porta MG, Pascutto C, et al. “Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making”. J Clin Oncol. 2005;23:7594-7603.

52. Mazza P, Giua R, De Marco S, et al. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of liver. Haematologica. 1995;80:398-404.

53. Mckay PJ, Murphy JA, Cameron S, Burnett AK, Campbell M, Tansey P, et al. Iron overload and liver dysfunction after allogenic or autologous bone marrow transplantation. Bone Marrow Transplant. 1996;17:63-66. pmid: 8673057.

54. Miceli MH, Dong L, Grazziutti ML, Fassas A, Thertulien R, Van Rhee F, Barlogie B, Anaissie EJ. Bone Marrow Transplant. 2006;37(9):857-64. doi: 10.1038/sj.bmt.1705340.

55. Morrison ED, Brandhagen DJ, Phatak PD, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med. 2003;138:627-33. pmid: 12693884.

56. National Heart, Lung, and Blood Institute. The Management of Sickle Cell Disease. 4th ed. Bethesda, Md: National Institutes of Health; 2002. NIH publication 02-2117.

57. National Institutes of Health, National Heart, Lung, and Blood Institute: The Management of Sickle Cell Disease. 2002, Bethesda, MD: NIH.

58. Nemeth E, Ganz T. Regulation of Iron Metabolism by Hepcidin. Annual Review of Nutrition. 2006;26:323-342. doi: 10.1146/annurev.nutr.26.061505.111303.

59. Nielsen P, Fischer R, Engelhardt R, et al. Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone. Br J Haematol. 1995;91(4):827-33. pmid: 8547125.

60. O’Relly R. Iron overload: Transplant populations at risk. BMT Tandem meeting, feb 2008.

61. Oliveri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-talassemia. N Engl J Med. 1994;331:574-578.

62. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331(9):574-8.

63. Olsson KS, Norrby A. Comment to: Hepcidin: from discovery to differential diagnosis. Haematologica. 2008;93:90-7. doi: 10.3324/haematol.12814.

64. Piga A, Fischer R, St Pierre T, et al. Comparison of LIC obtained from biopsy, BLS and R2-MRI in iron overloaded patients with β-thalassemia, treated with deferasirox (Exjade®, ICL670). Blood. 2005;106(11):abst2689.

65. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873-880.

66. Pootrakul P, Kitcharoen K, Yansukon P, et al. The effect of erythroid hyperplasia on iron balance. Blood. 1988;71(4):1124-9.

67. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115(2):239-52.

68. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennet CL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 Fmtrican Society of Hematology/American Society of Clinical Oncology clinical practice guidelines update. Blood. 2008;111:25-41. doi: 10.1182/blood-2007-08-109488.

69. Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoetic cell transplantation: joint recommendations of the European group for blood and marrow transplantation, the center for international blood and marrow transplant research, and the American society of blood and marrow transplantation. Biol Blood and Marrow Transplant. 2006;12:138-151.

70. Roeser HP, Halliday JW, Sizemore DJ, et al. Serum ferritin in ascorbic acid deficiency. Br J Haematol. 1980;45(3):459-66. pmid: 7426434.

71. Sahlstedt L, Ebeling F, Bonsdorff L, et al. Non-transferrin-bound iron during allogeneic stem cell transplantation. Br J Haematol. 2001;113:836-838.

72. Schmitt B, Golub RM, Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med. 2005;143:522-36.

73. Strasser SI, Kowdley KV, Sale GE, et al. Iron overload in bone marrow transplant recipients. Bone Marrow Transplant. 1998;22:167-173.

74. Swinkels DW, Janssen MCH, Bergmans J, Marx JJM. Hereditary Hemochromatosis: Genetic Complexity and New Diagnostic Approaches. Clin. Chem. 2006;52:950-968.

75. Takatoku M, Takashi U, Shinichiro O, Kanakura O, Sawada K, Tomonaga M, Nakao S, Nakahata T, Harada M, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. European Journal of Haematology. 2007;78(6):487-494.

76. Tomás JF, Pinilla I, Garca-Buey ML, et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow Transplantation. 2000;26:649-655.

77. Townsend A, Drakesmith H. Role of HFE in iron metabolism, hereditary haemochromatosis, anaemia of chronic disease, and secondary iron overload. Lancet. 2002;359:786-790. doi: 10.1016/S0140-6736(02)07885-6.

78. Valent P, Krieger O, Stauder R, Wimazal F, Nösslinger T, Sperr WR, Sill H,  Bettelheim P and Pfeilstöcker M. Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. European Journal of Clinical Investigation. 2008;38:3,143–149. doi: 10.1111/j.1365-2362.2007.01915.x.

79. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136:501-508. doi: 10.1111/j.1365-2141.2006.06455.x.

80. Zurlo M.F, DeStefano P, Borgna-Pignatti C. Survival and causes of death in thalassaemia major. Lancet. 1989;2:27-30.

Volume 1, Number 3

Download PDF version

doi 10.3205/ctt-2009-en-000037.01
Submitted 19 January 2009
Accepted 12 October 2009
Published 30 December 2009

Back to the list